Chiesi’s asthma drug reduces severe exacerbations

Chiesi Spain and Portugal present new therapeutic solution for maintenance treatment in asthmatic patients who are not adequately controlled. The launch of a new indication for one of the drugs means expansion portfolio of triple ultra-fine fixed treatments company, the range is focused on meeting the needs of patients with asthma and chronic obstructive pulmonary disease (COPD) from the small airways.

He 70 percent of patients In asthma, the disease is only partially controlled or uncontrolled, and more than 90 percent of patients have possible changes in the small airways (SAF). Likewise, according to the Spanish Federation of Allergy and Respiratory Patients Associations (Fenaer), asthma affects about 340 million people in the world, already about 3 million in Spain.

Trimbow 87/5/9 mcg Its formula consists of ultra-fine particles that allow the active ingredients to reach the PVA (small airways). Based on phase III studies, Trimbow 87/5/9 mcg has been shown to be an effective therapeutic option for improving Lung function in patients with asthma not controlled by the CI+LABA combination, especially the positive effect in reducing the frequency of moderate and severe exacerbations. A joint analysis of key studies found that Trimbow can reduce the incidence of severe exacerbations by 23 percent (p=0.008) and the risk of their occurrence by 21 percent. It has also been shown to provide greater benefit to certain subgroups of asthma patients, supporting a possible personalized approach to the disease.

Strengthens its portfolio of respiratory solutions.

With this new release, Chiesi strengthens its catalog of respiratory solutions offer asthma patients a variety of treatment options, devices and dosages that best suit their needs. The company remains strongly committed to the health and quality of life of patients with respiratory diseases through research and development. development of therapeutic solutions.

“The patient is at the center of everything we do and working to improve their well-being and quality of life is what drives us and motivates to create therapeutic solutions tailored to your needs. This launch reinforces our responsibility as a pharmaceutical company and our efforts to lead the research and development of medicines and services for patients. Additionally, it allows us to consolidate our Trimbow line as recommendations for asthma treatment and COPD from the small airways,” explains Dolors Querol, Medical and Technical Director at Chiesi Spain.

This progress in asthma research led to the “Building the Future of Asthma Together” meeting, organized by Chiesi. During the conference, medical specialists in the field of respiratory pathologies exchanged knowledge about the latest trends and developments in the treatment of asthma, reflecting on the future challenges of this pathology and how improve patient adherence and treatment management.

For his part, Vicente Plaza, director of the pulmonology service at the Santa Creu e Sant Pau Hospital in Barcelona, ​​explains that “ technology and medical research have a major impact on the future of asthma treatment and management”: “In pharmacological research, the development of new monoclonal antibodies for the treatment of severe asthma meant a revolution, and even more so in a segment where it was more needed, since until now the available therapeutic offer was minimal. Moreover, as one might expect, the technological impact that introduction of artificial intelligence It will be significant both in the clinical management of patients and in the diagnostic and therapeutic processes. I am convinced that we are at the beginning of a cycle change, a new technological era as applied to medicine. The future has already begun.”

Similarly, Carolina Cisneros of the Department of Pulmonology at La Princesa University Hospital in Madrid notes that “the fundamental reason low therapeutic adherence In asthma, there is a lack of adequate information from doctors about the inflammatory phenomenon that causes asthma and the importance of inhalation treatment to prevent relapses of the disease. It is also worth highlighting fear of side effects and the so-called “corticophobia” and, finally, fatigue caused, especially in young patients, by chronic treatment, especially when the patient does not feel the symptoms of the disease.”

“From a more general point of view, in addition to the important development of new molecules and devices What has happened in recent years, the development of technology itself is one of the most significant advances in the field of asthma treatment. For example, the impact of small-caliber air ducts on asthma is already being assessed. pulse oscillometry, a method that is easy for patients to use and which helps us, especially in cases of poorly controlled asthma. Molecular diagnostics in patients with Allergic asthma, which requires a specific allergen to which the patient is sensitized, or new imaging techniques with very high quality and lower radiological dose. Similarly, with an emphasis on the patient as the main participant in the process, strategies for using virtual tools are being implemented to facilitate the interaction of the doctor, nurse and patient specialist, evaluate long-term evolution of lung function or improve adherence to inhaled treatments or biological medications in cases of severe asthma,” explains Javier Domínguez, head of the allergy department at La Paz University Hospital in Madrid.